TICKERNERD
Menu
RNACRNACHealthcare · Biotechnology

RNAC Stock Forecast: Cartesian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$6.34
−3.50% on the day

The 7 Wall Street analysts covering Cartesian Therapeutics, Inc. hold a median 12-month price target of $39 — +507.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$211.5M
Ticker Nerd rank
27 / 100
Median analyst target
$39
Analysts covering
7
Revenue$0.0−100.0% y/y
Operating income−$29.2M
Net income$15.8M
Free cash flow−$21.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−21.1%
YTD
−12.1%
1Y
−32.7%
From 52W high
−40.1%
From 52W low
+8.6%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RNAC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cartesian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Size
68
Revisions
45
Momentum
45
Volatility
39
Value
39
Quality
32
Growth
8
Issuance
7

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RNAC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNAC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26RNACHigh $44Median $39Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $16Median $39High $44

The green dot is the last close — the median target sits +507.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Sept 2026HC Wainwright & Co.ReiteratesBuy$25
29 Sept 2026NeedhamReiteratesBuy$40
18 Aug 2026WedbushReiteratesOutperform—
18 Aug 2026WedbushReiteratesOutperform$38
10 June 2026WedbushReiteratesOutperform—
10 June 2026WedbushReiteratesOutperform$38
9 June 2026BTIGReiteratesBuy$44
9 June 2026BTIGReiteratesBuy—
9 June 2026NeedhamReiteratesBuy$40
9 June 2026NeedhamReiteratesBuy—
27 May 2026WedbushReiteratesOutperform—
26 May 2026NeedhamMaintainsBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026WedbushReiteratesOutperform—
10 Mar 2026WedbushReiteratesOutperform—
9 Mar 2026Cantor FitzgeraldUpgradeOverweight—
9 Mar 2026NeedhamReiteratesBuy—
9 Jan 2026NeedhamMaintainsBuy—
19 Nov 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNAC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RNAC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Cartesian Therapeutics, Inc. returned −32.7% against +17.5% for the S&P 500, dividends included.

RNAC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26RNACS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RNAC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cartesian Therapeutics, Inc. (RNAC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.0×

Cheaper than 69% of US stocks

Price / sales
136.0×

Cheaper than 3% of US stocks

Price / book
−1.6×

Cheaper than 95% of US stocks

EV / EBITDA
−1.3×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−0.7%

Higher than 35% of US stocks

Gross margin
—
Operating margin
−6679.7%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
103.2%

Higher than 96% of US stocks

Return on assets
−17.4%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cartesian Therapeutics, Inc. (RNAC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cartesian Therapeutics, Inc. has a market value of $211.5M and an enterprise value of $127.7M.

  • Revenue in the twelve months to 30 June 2026: $1.5M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$151.9M, a −10283.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$78.6M.

  • Shares outstanding: 30.0M.

  • Trailing P/E: 2.0×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cartesian Therapeutics, Inc. employs 75 people — $20K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

RNAC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNACCartesian Therapeutics, Inc.$211.5M
27
UPBUpstream Bio, Inc.$187.3M
25
ACOGAlpha Cognition, Inc.$188.4M
55
ELDNEledon Pharmaceuticals, Inc.$182.8M
33
SIONSionna Therapeutics, Inc.$182.5M
28
CGENCompugen Ltd.$189.1M
86
IVVDInvivyd, Inc.$179.1M
16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cartesian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNAC news & analysis

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewsWire · 2 Oct 2026neutral

Cartesian Therapeutics announced it granted inducement awards to four new employees on October 1, 2026, consisting of options to purchase an aggregate of 121,900 shares of common stock at an exercise price of $7.22. The options, approved by the board of directors, vest over a multi-year schedule and have a ten-year term, granted under Nasdaq Rule 5635(c)(4) as an employment inducement.

Why it matters — A RNAC watcher would note this as a routine equity-based inducement action tied to new hires, reflecting standard compensation practice with no immediate operational or financial impact.

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

GlobeNewsWire · 29 Sept 2026positive

Cartesian Therapeutics announced additional retreatment data for its investigational therapy Descartes-08 in patients with myasthenia gravis. The data showed improvement in mean change from baseline on the MG-ADL scale, including a mean reduction of 6.6 points at Month 12 following retreatment, highlighting deep and durable responses.

Why it matters — RNAC watchers would care because the data reinforce the durability and depth of Descartes-08's responses in myasthenia gravis, a key clinical and regulatory development for the company's pipeline.

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewsWire · 8 Sept 2026neutral

Cartesian Therapeutics announced the granting of employment inducement awards to three new employees. The company is a late clinical-stage biotechnology firm focused on cell therapy for autoimmune diseases.

Why it matters — This signals new hiring at Cartesian, which may be relevant for RNAC watchers tracking the company's personnel and operational developments.

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a late clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, announced that its management expects to participate in several investor conferences scheduled for September.

Why it matters — RNAC watchers may be interested as the company's management will be presenting at upcoming investor conferences, potentially providing updates on its pipeline.

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewsWire · 7 Aug 2026neutral

Cartesian Therapeutics announced it granted inducement stock option awards to four new employees, covering an aggregate of 115,250 shares of its common stock, with effective grant dates of August 3, 2026 and August 6, 2026.

Why it matters — A Cartesian Therapeutics watcher would note that the company is adding new hires through equity-based inducement awards as it advances cell therapy for autoimmune diseases.

FAQ

Frequently asked questions about RNAC stock

What is the RNAC stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Cartesian Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $16 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNAC stock a buy right now?

Of the 7 analysts covering Cartesian Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cartesian Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNAC?

As at 14 Oct 2026, Cartesian Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will RNAC stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +507.3% from the last close, and Ticker Nerd's factor model ranks Cartesian Therapeutics, Inc. 27 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNAC stock forecast for 2030?

No analyst covering Cartesian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $44 over the next 12 months.

How has RNAC stock performed over the past year?

Cartesian Therapeutics, Inc. returned -32.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cartesian Therapeutics, Inc. do?

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases.

What is the latest news on RNAC?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Cartesian Therapeutics Announces New Employment Inducement Grants". Cartesian Therapeutics announced it granted inducement awards to four new employees on October 1, 2026, consisting of options to purchase an aggregate of 121,900 shares of common stock at an exercise price of $7.22. The options, approved by the board of directors, vest over a multi-year schedule and have a ten-year term, granted under Nasdaq Rule 5635(c)(4) as an employment inducement.

Company

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s current pipeline centers on autologous CAR-T programs designed to modulate immune activity and address serious conditions such as generalized myasthenia gravis, systemic lupus erythematosus, and certain forms of myositis. Its lead candidate, Descartes-08, is being advanced across multiple autoimmune indications, while additional programs such as Descartes-15 and Descartes-33 expand the company’s research beyond its lead asset. Cartesian Therapeutics emphasizes engineered cell therapy and proprietary manufacturing capabilities to create targeted treatments that fit within the broader fields of immunology, cell therapy, and precision medicine. Headquartered in Frederick, Maryland, Cartesian Therapeutics plays a specialized role in the biotechnology market by focusing on advanced therapies for difficult-to-treat immune-mediated diseases.

CEO Dr. Carsten Brunn Ph.D. · 75 employees · United States · https://www.cartesiantherapeutics.com